Evidence map›Paper›PMID 41098140›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.

Ornina Atieh, Joviane Daher, Marc Abboud, Qian Wu, Abdus Sattar, Jhony Baissary, Ziad Koberssy, Danielle Labbato, Allison Ross Eckard, Grace A McComsey

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04019197. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04019197 phase2active not recruiting

Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy

Ran2019Enrolled108Registered outcomes49Posted comparisons48ConditionsHIV/AIDS, Lipohypertrophy, ObesityArmsPlacebo, Semaglutide Injectable Product
Open the trial in the graph
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ornina AtiehDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Joviane DaherDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0007-9008-4066
Marc AbboudFaculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Qian WuDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Abdus SattarDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-3863-3113
Jhony BaissaryDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Ziad KoberssyDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0002-6819-1926
Danielle LabbatoClinical Research Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Allison Ross EckardPediatric Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina, USA.
Grace A McComseyDivision of Infectious Diseases, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-2690-8888

Funding

Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophyR01DK121619 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ECKARD, ALLISON ROSS, MCCOMSEY, GRACE A · 2019 to 2023
$3.8M
NIDDK NIH HHS R01 DK121619NIH HHS
6 · The paper itself

Abstract

backgroundPeople with human immunodeficiency virus (HIV, PWH) are at higher risk for visceral adiposity, enhanced inflammation, and cognitive decline than controls who do not have HIV. We previously demonstrated that PWH with lipohypertrophy had a decrease in weight, visceral adipose tissue, and several inflammatory markers after receiving semaglutide, a glucagon-like peptide-1 receptor agonist. Our aim was to investigate the effect of semaglutide on cognitive function in PWH and the possible mediation of this effect by changes in adiposity or inflammation.

methodsIn this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo. The primary outcome was the change in cognitive function at 32 weeks. Secondary measures included changes in body composition and inflammatory markers. Causal mediation analysis assessed semaglutide's direct and indirect effects on Cognivue scores through changes in adiposity and inflammation.

results108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years. Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively). After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05). Semaglutide's total natural direct effect maintained a positive effect on the visuospatial score while accounting for potential changes in high-sensitivity C-reactive protein and soluble CD163 levels (P = .04).

conclusionsSemaglutide may have a beneficial impact on visuospatial cognitive function in PWH through its effect on inflammation. Clinical Trials Registration . NCT04019197.

Indexed as

CognitionGlucagon-Like PeptidesHIV InfectionsAdiposityAdultDouble-Blind MethodFemaleHumansInflammationMaleMiddle AgedGlucagon-Like Peptidescognitive functionCognivueglucagon-like peptide-1 receptor agonistpeople with HIVPWH

Identifiers

PMID41098140
PMCPMC13189676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.